Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab in chronic migraine
NCT02021773Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2014
- Primary completion
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of fremanezumab in chronic migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Jan 2014; status: completed.
02
Drugs
fremanezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02021773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021773.